Large deletions 5′ to the ETO breakpoint are recurrent events in patients with t(8;21) acute myeloid leukemia

被引:18
作者
Godon, C
Proffitt, J
Dastugue, N
Lafage-Pochitaloff, M
Mozziconacci, MJ
Talmant, P
Hackbarth, M
Bataille, R
Avet-Loiseau, H
机构
[1] Univ Hosp Nantes, Hematol Lab, Nantes, France
[2] Vysis Inc, Downers Grove, IL USA
[3] Univ Hosp Toulouse, Cytogenet Unit, Toulouse, France
[4] Inst J Paoli I Calmettes, Cytogenet Lab, F-13009 Marseille, France
关键词
acute myeloid leukemia; cytogenetics; ETO; fluorescence in situ hybridization; deletion;
D O I
10.1038/sj.leu.2402585
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recurrent chromosomal rearrangements are observed in many leukemia subtypes. Recently, it has been shown that several of these translocations/inversions were associated with the loss of sequences located in the vicinity of the chromosomal breakpoints. So far, such deletions have not been described for the t(8;21) translocation. We have analyzed a series of 65 patients with t(8;21) using several probes specific for the ETO and AML1 regions. We have found six patients (9%) with deletion of the region 5' to ETO. In all six patients, the deletion encompassed at least 260 kb, and was even larger in two patients (up to 2 Mb). A similar analysis of the 21q22 region did not reveal any deletion of the 3' AML1 region. In conclusion, cytogenetically undetectable small deletions located immediately 5' to the ETO breakpoint were found to accompany the t(8;21) translocation in a significant percentage of cases. The clinical significance, if any, of these deletions remains to be determined.
引用
收藏
页码:1752 / 1754
页数:3
相关论文
共 15 条
[1]  
Bloomfield CD, 1998, CANCER RES, V58, P4173
[2]   Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered [J].
Byrd, JC ;
Dodge, RK ;
Carroll, A ;
Baer, MR ;
Edwards, C ;
Stamberg, J ;
Qumsiyeh, M ;
Moore, JO ;
Mayer, RJ ;
Davey, F ;
Schiffer, CA ;
Bloomfield, CD .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (12) :3767-3775
[3]   ACUTE LEUKEMIAS OF DIFFERENT LINEAGES HAVE SIMILAR MLL GENE FUSIONS ENCODING RELATED CHIMERIC PROTEINS RESULTING FROM CHROMOSOMAL TRANSLOCATION [J].
CORRAL, J ;
FORSTER, A ;
THOMPSON, S ;
LAMPERT, F ;
KANEKO, Y ;
SLATER, R ;
KROES, WG ;
VANDERSCHOOT, CE ;
LUDWIG, WD ;
KARPAS, A ;
POCOCK, C ;
COTTER, F ;
RABBITTS, TH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (18) :8538-8542
[4]   Deletion of the multidrug resistance-associated protein (MRP1) gene in acute myeloid leukemia with inversion of chromosome 16 has no prognostic impact [J].
Döhner, K ;
Schlenk, RF ;
van der Reijden, BA ;
Döhner, H .
LEUKEMIA, 2000, 14 (06) :1154-1154
[5]   The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial [J].
Grimwade, D ;
Walker, H ;
Oliver, F ;
Wheatley, K ;
Harrison, C ;
Harrison, G ;
Rees, J ;
Hann, I ;
Stevens, R ;
Burnett, A ;
Goldstone, A .
BLOOD, 1998, 92 (07) :2322-2333
[6]   World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November 1997 [J].
Harris, NL ;
Jaffe, ES ;
Diebold, J ;
Flandrin, G ;
Muller-Hermelink, HK ;
Vardiman, J ;
Lister, TA ;
Bloomfield, CD .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (12) :3835-3849
[7]   Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis [J].
Kolomietz, E ;
Al-Maghrabi, J ;
Brennan, S ;
Karaskova, J ;
Minkin, S ;
Lipton, J ;
Squire, JA .
BLOOD, 2001, 97 (11) :3581-3588
[8]   Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials [J].
Langabeer, SE ;
Walker, H ;
Rogers, JR ;
Burnett, AK ;
Wheatley, K ;
Swirsky, D ;
Goldstone, AH ;
Linch, DC .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 99 (04) :925-928
[9]   Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia [J].
Le Gouill, S ;
Talmant, P ;
Milpied, N ;
Daviet, A ;
Ancelot, M ;
Moreau, P ;
Harousseau, JL ;
Bataille, R ;
Avet-Loiseau, H .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (07) :1533-1538
[10]   MOLECULAR CHARACTERIZATION OF 16P DELETIONS ASSOCIATED WITH INVERSION-16 DEFINES THE CRITICAL FUSION FOR LEUKEMOGENESIS [J].
MARLTON, P ;
CLAXTON, DF ;
LIU, P ;
ESTEY, EH ;
BERAN, M ;
LEBEAU, M ;
TESTA, JR ;
COLLINS, FS ;
ROWLEY, JD ;
SICILIANO, MJ .
BLOOD, 1995, 85 (03) :772-779